Anti-cancer activity of dose-fractioned mPE +/- bevacizumab regimen is paralleled by immune-modulation in advanced squamous NSLC patients.
Pastina P, Nardone V, Croci S, Battaglia G, Vanni F, Bellan C, Barbarino M, Ricci V, Costantini S, Capone F, Botta C, Zarone MR, Misso G, Boccellino M, Caraglia M, Giordano A, Paladini P, Tassone P, Tagliaferri P, Cusi MG, Pirtoli L, Correale P.
Pastina P, et al. Among authors: boccellino m.
J Thorac Dis. 2017 Sep;9(9):3123-3131. doi: 10.21037/jtd.2017.08.68.
J Thorac Dis. 2017.
PMID: 29221287
Free PMC article.